In 2023, the FDA and CDC's Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the monoclonal ...

For pregnant women who received the bivalent prefusion F subunit-based respiratory syncytial virus (RSV) vaccine (RSVpreF; ...

A systematic review and meta-analysis finds that the definition of severe acute respiratory infection (SARI) used by the ...

Respiratory syncytial virus (RSV) is a common virus that affects the nose, throat, and lungs. For most healthy adults and ...

“Our findings indicate that the vaccine provided a significant enhanced level of protection against these infections in the ...

Scientists have uncovered strong evidence that infection with RSV in the first months of life can significantly raise the ...

A single dose of the recombinant respiratory syncytial virus (RSV) vaccine demonstrates effectiveness against infections and associated hospitalizations in veterans aged 60 years or older during the ...

In a recent final analysis of a phase 3 trial, the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine maintained high efficacy and a favorable safety profile against RSV-associated ...

How effective is nirsevimab at preventing respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD), ...

April 1 (Reuters) - The European Commission approved Pfizer's (PFE.N), opens new tab respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease caused by RSV in adults ...

Newsweek has created a map showing states where respiratory syncytial virus (RSV) cases are surging. In the week ending December 21, the following three states had the highest percentage of positive ...

RSV causes more severe respiratory infection than influenza in patients with malignancy, increasing risks for ICU admission and mortality.